NCT02350218

Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)

Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 76 (estimated)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate superiority of Eglandin® (Alprostadil) 720㎍compared to 360㎍ in terms of safety, efficacy in living donor liver transplant patient, peak AST levels followed by Eglandin administration were assessed.

Conditions

• Evidence of Liver Transplantation

Interventions

Type	Name	Description
DRUG	Eglandin	Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient

Timeline

• Start date: 2015-03-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2015-01-29
• Last updated: 2018-07-06

Locations

1 site across 1 country: South Korea